The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

CLINICAL INVESTIGATION OF CHLORPROMAZINE AND RESERPINE IN PRIVATE PSYCHIATRIC PRACTICE

Published Online:https://doi.org/10.1176/ajp.112.10.782

One hundred and eighty private psychiatric patients received reserpine or chlorpromazine as well as standard psychiatric therapies. Of this number, 94 were hospitalized patients and 86 were office (ambulatory) patients. Results were disappointing from the standpoint of either drug producing a recovery, but encouraging in that they were superior to barbiturates in producing symptomatic improvement in anxiety, tension, manic and schizophrenic excitement, and mild insomnia. Depression per se was not alleviated by either drug. Usually, where one drug was found ineffective, so was the other. There were a few serious side-effects in our series: jaundice in 5 patients given chlorpromazine; 2 cases of cardiac collapse, and several cases of ankle and facial edema in those given reserpine. In general, neither reserpine nor chlorpromazine appeared to potentiate or interfere with standard psychiatric therapies.

Six cases are singled out for special comment. In 2 cases of morphine addiction chlorpromazine administration prevented withdrawal symptoms. Alarming cardiac collapse occurred in 2 elderly patients on reserpine. In another case, exaggeration of former gastrointestinal symptoms appeared following reserpine administration. In the sixth case reserpine failed to control hypo-manic symptoms and probably potentiated postelectroshock confusion.

The clinical nature of this study of private patients, the large proportion of whom were cases of depressive reactions, must be considered in the evaluation of results of the 2 drugs. From this clinical experience a study of the use of the drugs in selected cases is planned.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.